| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18752 R79754 |
Moore (Gabapentin) (Mixed indications) (Controls exposed to LTG), 2025 | Pregnancy loss (pregnancy outcome other than live birth at any gestation, including spontaneous loss (miscarriage, stillbirth) and termination of pregnancy) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
1.49 [1.31;1.70] C excluded (control group) |
852/2,624 481/1,976 | 1,333 | 2,624 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18753 R79758 |
Moore (Gabapentin) (Mixed indications) (Controls unexposed, general pop), 2025 | Pregnancy loss (pregnancy outcome other than live birth at any gestation, including spontaneous loss (miscarriage, stillbirth) and termination of pregnancy) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Matched | 1.33 [1.21;1.46] | 852/2,624 5,952/25,691 | 6,804 | 2,624 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8500 R27931 |
Vajda (Controls exposed to Lamotrigine, sick), 2018 | Intrauterine foetal death | throughout pregnancy | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.94 [0.05;16.57] C excluded (control group) |
0/14 14/382 | 14 | 14 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8501 R27932 |
Vajda (Controls unexposed, sick), 2018 | Intrauterine foetal death | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 4.16 [0.16;107.12] C | 0/14 1/170 | 1 | 14 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8490 R27884 |
Miškov (Controls exposed to Lamotrigine, sick), 2016 | Fetal loss | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
2.41 [0.08;68.55] C excluded (control group) |
0/2 4/37 | 4 | 2 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8491 R27890 |
Miškov (Controls unexposed, disease free), 2016 | Fetal loss | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No |
85.00 [1.23;5885.76] C excluded (control group) |
0/2 0/128 | 0 | 2 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8492 R27896 |
Miškov (Controls unexposed, sick), 2016 | Fetal loss | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 2.33 [0.03;182.92] C | 0/2 0/4 | 0 | 2 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8485 R27853 |
Arkilo, 2015 | Unsuccessful pregnancies (miscarriages/stillbirths) | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick | Adjustment: No | 8.60 [0.14;536.34] C | 0/1 2/24 | 2 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 4 studies | 1.33 [1.21;1.46] | 6,807 | 2,641 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Gabapentin) (Mixed indications) (Controls unexposed, general pop; 2: Controls unexposed, sick; 3: Controls unexposed, sick;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 8490, 8491, 8500, 18752